KEDI Global Obesity Care Industry Top 2+ Index

First quarter 2026 earnings release is scheduled.

Q1 2026 earnings release on 2026-05-07 is scheduled. A typical 1-2% price movement is estimated.

First quarter 2026 financial results announcement scheduled.

First quarter 2026 earnings release and conference call, which is estimated to have a >=10% price impact, is scheduled.

Merck will report Q1 2026 earnings and host its earnings call on 2026-04-30, which is likely to be material given the strong market sensitivity to its recent guidance outlook, scheduled.

First quarter 2026 earnings results, with low impact expected from the date announcement, scheduled

Abbott's first-quarter 2026 financial results announcement and conference call on April 16, 2026, for which market analysts estimate a >=5% price impact, are scheduled.

U.S. Food and Drug Administration (FDA) decision on orforglipron, an oral weight-loss pill, is expected. The target action date was previously extended, and a >=10% price impact is expected.

Company management will participate in a fireside chat at the J.P. Morgan 12th Annual Retail Round Up, scheduled.

Quarterly dividend of $1.25 per share, representing a 3% increase, went ex-dividend on March 27, 2026. The dividend was announced on March 11, 2026.

The stock goes ex-dividend for a final dividend of DKK 7.95 per share for the 2025 fiscal year on 2026-03-27.

Telehealth platform Hims & Hers announced it will offer Novo Nordisk's branded GLP-1 drugs Wegovy and Ozempic, resolving a prior legal dispute over compounded versions.

Announced positive topline results from a Phase 2 trial in China for UBT251, a 'triple G' agonist, showing superior blood sugar and weight reduction compared to semaglutide in patients with type 2 diabetes.

S&P Global Ratings is expected to downgrade Abbott's credit rating to 'A+' from 'AA-' on March 24, 2026, following the Exact Sciences acquisition; market analysts estimate a >=10% price impact.

Announced plans to invest over $460 million (CNY 3.3 billion) to upgrade its manufacturing and R&D facilities in China.